An Analysis of the Clinical Benefit of Chemotherapy & Xtandi Post Zytiga in Men with Metastatic Castration Resistant Prostate Cancer
The FDA approved Abiraterone acetate (Zytiga) plus prednisone because it demonstrated a survival benefit for men with metastatic castrate resistant prostate cancer (mCRPC) in the pre-chemotherapy setting. Given the newness of the approval of Zytiga [...]
Nadir PSA Levels and Time to Achieving Nadir Are Significant Prognostic Factors
Hormone therapy or Primary androgen deprivation therapy (PADT) is the usual first “go to” therapy for men when they are diagnosed with metastatic prostate cancer whether it is a primary diagnosis or the result of [...]
What you Need to Know About Denosumab (Xgeva)
Xgeva is used in men with advanced and metastatic prostate cancer with bone metastases for the prevention of developing additional skeletal-related events (not to be confused with bone mineral density). In a phase 3 trial, [...]
Finding BioMarkers to Drug Sensitivity, The Next Step – ASCO Annual Meeting at ASCO GU
Now that we have new treatments available to fight advanced, metastatic prostate cancer we need ways to decide on the best treatments given that many of the treatments occupy the same disease space. This is [...]
TAK-700 Fails to Offer A Survival Extension
Much of my reporting about ASCO 2014 has included only positive studies, but there is always a share of studies and trials that do not prove to be of a direct positive value to men [...]
ASCO 2014 – Exercise Cuts Cytokines in Prostate Cancer
Research released at the ASCO meeting in Chicago confirms that regular exercise is a must for men with advanced prostate cancer. It was found that a regular and structured physical exercise program reduces cytokine production [...]